In the latest development in the “highly dynamic” molecular glue space, Merck KGaA has inked a discovery agreement with C4 Therapeutics for two protein degraders against cancer targets.
C4 will receive $16 million upfront and is eligible for up to $740 million in milestones and tiered royalties on sales ranging…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
